How to Get a GLP-1 Prescription: Every Legitimate Route

A GLP-1 such as Wegovy, Zepbound, Ozempic or Foundayo is a prescription medicine: all doses of Wegovy and Ozempic require a prescription whether you self-pay or go through insurance, so there is no over-the-counter route for those brands ^[7]. The clinicians who treat obesity with medication include physicians, nurse practitioners, physician assistants and other healthcare providers with specialized training in obesity care ^[5]. The Wegovy label lists a DEA Schedule of “None,” meaning it is not a controlled substance ^[1].

There are five legitimate routes from “interested” to “filling a prescription”: your regular primary care doctor, a diabetes or obesity specialist, a telehealth service that prescribes the FDA-approved brand, a manufacturer’s direct pharmacy such as NovoCare Pharmacy or LillyDirect, or — for Medicare Part D beneficiaries who qualify — the Medicare GLP-1 Bridge, which runs from July 1, 2026 through December 31, 2027 with a $50 copay ^[8]. Employer insurance sits underneath several of these routes as the payment layer. Compounded copies, salt forms and “research-only” products are not legitimate routes for routine use, and the FDA has spelled out why ^[9].

Who is allowed to prescribe a GLP-1?

The Obesity Medicine Association’s membership includes physicians, nurse practitioners, physician assistants and other healthcare providers who treat obesity and obesity-related conditions ^[5], which reflects who actually writes these prescriptions in practice. The Wegovy label lists a DEA Schedule of “None,” meaning it is not a controlled substance ^[1].

Family physicians are often the first line of treatment in the healthcare setting, which gives them early opportunities to prevent or treat overweight and obesity ^[3]. Novo Nordisk states plainly that all doses of Wegovy and Ozempic require a prescription, whether you pay yourself or go through insurance ^[7].

What must a prescriber do when the GLP-1 is an injection?

The drug labels impose one requirement every prescriber of an injectable GLP-1 must meet: training the patient on the specific device. The Wegovy label directs prescribers to inform patients and caregivers which presentation they will receive — a single-dose pen, a single-dose syringe, or the multi-dose FlexTouch pen — and to ensure training appropriate to that presentation, with retraining if the presentation changes ^[1].

The Zepbound label says the same for its presentations (vial, single-dose pen, or KwikPen): train the patient or caregiver on injection technique before the medication is started ^[2]. Two device-specific points from the labels: the Wegovy FlexTouch and Zepbound KwikPen are not recommended for self-administration by people who are visually impaired ^[1][2], and Zepbound vial users need an appropriate syringe — a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose — with a new syringe and needle for every injection ^[2].

Can my primary care doctor prescribe Wegovy or Zepbound?

Yes. A joint 2025 review from the Obesity Medicine Association and the American College of Osteopathic Family Physicians describes family physicians as often the first line of treatment, and frames primary care as the place where obesity is recognized, diagnosed and treated using four pillars: nutrition therapy, physical activity, behavior modification, and medical interventions such as anti-obesity medications and bariatric surgery ^[3].

The same review is candid about why some primary care offices hesitate. Barriers it lists include failure to recognize obesity as a disease, lack of an accurate diagnosis, insufficient access to treatment resources, inadequate training, insufficient time, inadequate reimbursement, and the effects of bias and stigma ^[3]. It also notes that staff training is often required to navigate prior authorizations from insurers that do cover anti-obesity medications ^[3]. None of these barriers means a primary care clinician cannot prescribe — they explain why experiences differ from office to office.

For monitoring, the American Diabetes Association’s 2026 Standards of Care recommends screening BMI annually, and increasing monitoring to at least every 3 months during active weight management ^[4].

What if I have type 2 diabetes?

If type 2 diabetes is part of the picture, the ADA’s recommendations point toward these drugs directly. In people with diabetes and overweight or obesity, the preferred pharmacotherapy is semaglutide or tirzepatide — the molecules in Wegovy/Ozempic and Zepbound/Mounjaro — a grade A recommendation ^[4]. The ADA also states that weight management should be a primary treatment goal alongside glycemic management ^[4].

Two more ADA points shape what a prescriber does after the prescription: obesity pharmacotherapy intended for chronic therapy should be continued beyond weight loss goals, because stopping often leads to weight regain ^[4]; and the dose and titration approach should be individualized, since the optimal dose may not be the maximum approved dose ^[4].

How do I find an obesity medicine specialist?

The Obesity Medicine Association runs a member directory searchable by city, state or zip code ^[5]. Within the directory there are filters for an “ABOM Diplomate” — a doctor who has completed at least 60 hours of obesity-specific education and passed the American Board of Obesity Medicine certification exam — and a “Fellow of OMA,” a physician, nurse practitioner or physician assistant with at least 75 hours of advanced training in obesity medicine ^[5].

The OMA had over 5,000 members at the time of print in 2025 ^[3]. OMA members are also listed in the Obesity Action Coalition’s Obesity Care Provider Database, which additionally includes dietitians and bariatric surgeons ^[5].

Can I get a GLP-1 prescription online?

Yes, and telehealth has changed who gets access: a 2026 report in the Journal of Medical Internet Research notes that while these drugs were once accessible mainly to type 2 diabetes patients under specialist care, telehealth platforms now make them available to anyone with a BMI in the overweight or obese range ^[6].

The results reported in JMIR come from a large study of over 50,000 telehealth participants: 8.9% average weight loss at 3 months and 19% at 12 months, results the report describes as similar to major clinical trials ^[6].

The catch is what happens after the prescription. The JMIR report highlights a clinical support gap: platforms do not always offer the nutrition, exercise and behavioral guidance patients need, and some patients lose lean tissue and develop micronutrient deficiencies ^[6]. A scoping review in Obesity Reviews of 12 trials found that 40% of the weight lost was lean tissue, and only 3 of the 12 trials involved a registered dietitian ^[6]. The review’s authors recommend early dietitian involvement and a hybrid model that pairs telehealth prescriptions with clinical support ^[6].

The ADA’s Standards of Care addresses the same issue from the counseling side: high-frequency counseling (16 or more sessions in 6 months) is recommended when available, and if access to such interventions is limited, structured remote, telehealth or app-based programs are described as an alternative ^[4].

What are manufacturer direct pharmacies, and what do they cost?

NovoCare Pharmacy and LillyDirect are dispensing routes for the FDA-approved brands, not separate drugs. With NovoCare, the options include connection to a prescriber through telehealth, pharmacy pickup, or free home delivery once a prescriber sends the prescription to NovoCare Pharmacy ^[7]. These are promotional self-pay offers with eligibility terms and expiry dates, and Novo Nordisk states it reserves the right to modify or cancel the program at any time ^[7].

NovoCare Pharmacy self-pay pricing for Wegovy, where one month means 30 tablets or one box of pens ^[7]:

Product and dose	Self-pay price per month
Wegovy pill, 1.5 mg	$149 [7]
Wegovy pill, 4 mg	$199 [7]
Wegovy pill, 9 mg and 25 mg	$299 [7]
Wegovy pen, 0.25 mg and 0.5 mg	$199 for two monthly fills through December 31, 2026, then $349 [7]
Wegovy pen, 1 mg, 1.7 mg and 2.4 mg	$349 [7]
Wegovy pen, 7.2 mg (Wegovy HD)	$399 [7]

With commercial insurance, Novo’s savings offer can bring the cost to as little as $25 per month for up to 3 months, subject to a maximum savings of $100 per month; government beneficiaries are excluded ^[7].

On the Lilly side, Foundayo (orforglipron) became available via LillyDirect with prescriptions accepted April 1, 2026 and shipping from April 6, 2026; self-pay starts at $149 per month for the lowest dose, and eligible people with commercial coverage may pay as little as $25 per month with a savings card ^[15].

Does Medicare cover Wegovy or Zepbound for weight loss?

For Part D beneficiaries who qualify, yes — through a temporary program called the Medicare GLP-1 Bridge. The CMS demonstration runs from July 1, 2026 through December 31, 2027, and eligible beneficiaries pay a $50 copay ^[8]. The Bridge was extended through December 31, 2027 after the BALANCE Model did not launch in 2027 ^[8].

The covered products are the Foundayo tablet, the Wegovy injection or tablet, and the Zepbound KwikPen only — the program does not cover single-dose Zepbound vials or pens ^[14].

Eligibility, as Medicare.gov states it, requires being 18 or older and meeting one of these when starting therapy ^[14]:

• BMI of 35 or higher.
• BMI of 30 or higher with at least one of: diastolic heart failure, uncontrolled high blood pressure, or chronic kidney disease at stage 3a or higher.
• BMI of 27 or higher with at least one of: prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease.

The program excludes people already getting GLP-1 drugs covered through their Part D plan, and people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease — though a Part D plan might cover GLP-1s for those conditions ^[14].

Because the Bridge operates outside the Part D payment flow, the Part D deductible does not apply, no part of the $50 copay counts toward TrOOP costs, and there is no low-income subsidy for LIS beneficiaries ^[8]. In 2026, CMS uses a single central processor to manage prior authorization, claims adjudication and pharmacy payment ^[8].

What does a provider have to do for the Medicare Bridge?

The mechanics sit with the prescriber and pharmacy. The provider sends the prescription to the pharmacy, completes a prior authorization when requested, and certifies that the GLP-1 is being used as part of a lifestyle program focused on diet and exercise ^[14]. Once approved, the prior authorization is valid — including refills and dose changes — through December 31, 2027, unless the GLP-1 is changed, and an approval letter arrives by mail ^[14].

Medicare.gov tells beneficiaries who think they qualify to talk with their provider to get started, and lists 1-800-MEDICARE for eligibility questions or checking prior authorization status ^[14]. Lilly has stated that eligible Part D individuals may be able to get Foundayo for $50 per month beginning as soon as July 1, 2026 ^[15].

Will employer insurance cover a GLP-1, and how long does approval take?

A survey of 105 employer members of the Business Group on Health, completed February to March 2026, found that 67% cover GLP-1s for weight management ^[13]. Of those covering, 72% said they were likely to continue in 2027 and 10% said they likely would not; employers not covering today were described as unlikely to add coverage ^[13].

Plans that cover GLP-1s commonly use utilization management: validating clinical eligibility with objective biometric data, requiring participation in a weight management program, limiting prescribing to specific providers, and formulary exclusions ^[13]. Most (83%) use the same standard cost-share arrangement as for other medications ^[13].

How long a prior authorization decision takes is not stated in the sources cited here — they give no timeline for insurer decisions. What is known is that once a Medicare Bridge prior authorization is approved, it holds through December 31, 2027 including refills and dose changes ^[14].

What is not a legitimate route?

Compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before marketing; the FDA says compounding is appropriate only when a patient’s medical need cannot be met by an FDA-approved drug ^[9]. The salt forms sold by some compounders — semaglutide sodium and semaglutide acetate — are different active ingredients from the approved drugs, and the FDA is aware of no lawful basis for their use in compounding ^[9].

The harm is documented. As of May 31, 2026, the FDA had received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide, and the agency notes underreporting is likely ^[9]. Reported problems include dosing errors from patients self-measuring doses, some requiring hospitalization, and products labeled “for research purposes” or “not for human consumption” sold directly to consumers — products of unknown quality ^[9].

The FDA has also reminded telehealth companies not to market compounded GLP-1s with false or misleading claims: no claiming a compounded drug is a generic or the same as an FDA-approved drug, no claiming it is FDA-approved or clinically proven to produce the same result, and no claiming it comes from an FDA-approved or FDA-licensed pharmacy — the FDA does not approve or license any facility ^[10].

Has counterfeit Ozempic reached US pharmacies?

Yes, three times that the FDA has announced. On December 21, 2023, the FDA reported thousands of units of counterfeit Ozempic 1 mg seized, with lot NAR0074 and serial number 430834149057; analysis found the needles were also counterfeit and their sterility could not be confirmed ^[11]. On April 14, 2025, the agency reported several hundred units with lot PAR0362 and serial numbers starting 51746517, seized on April 9, 2025 ^[11].

On December 5, 2025, the FDA reported dozens of units of counterfeit Ozempic 1 mg labeled with lot PAR1229 — which is also an authentic lot number. The counterfeit can be identified by the EXP/LOT text placement: on the counterfeit it appears to the left of the expiration date and lot number, while the authentic pen has it above ^[11]. The FDA’s standing advice is to obtain Ozempic only with a valid prescription through state-licensed pharmacies ^[11].

How do I judge whether a seller or platform is legitimate?

The FDA’s red flags for telehealth sellers are specific: no screening and no prescription by a licensed doctor before providing medicine; no licensed doctor available to answer questions afterward; deep discounts or prices that seem too good to be true; medicine that looks different from what was received before or arrives in damaged packaging; and labels with spelling errors or a wrong pharmacy address ^[9].

The FDA’s recommendation is to obtain a prescription from a doctor and fill it at a state-licensed pharmacy ^[9]. Its BeSafeRx campaign includes a “Locate a State-Licensed Online Pharmacy” tool, a way to report unlawful sales, and MedWatch for reporting side effects ^[12]. For multi-dose vials, the FDA recommends discarding them 28 days after first use, even if medication remains, and using a new sterile needle and syringe for each dose ^[9]. Novo Nordisk puts it another way: if it is not made by Novo Nordisk, it is not FDA-approved Wegovy or Ozempic ^[7].

Which route fits which situation?

There is no single ranking, and the ADA recommends individualizing the initial approach based on medical history, life circumstances and preferences ^[4]. The president and CEO of the Obesity Action Coalition has said the same in plainer words: there is no single path that works for everyone living with overweight or obesity ^[15].

Some pairings follow from the facts above. Where type 2 diabetes is involved, the ADA’s preferred pharmacotherapy guidance points to semaglutide or tirzepatide under a prescriber managing the diabetes ^[4]. For Medicare Part D beneficiaries who meet the Bridge criteria, Medicare.gov says the starting point is a conversation with their provider ^[14]. Where cost is the barrier and commercial insurance is in place, the manufacturer savings offers ($25 per month for up to 3 months at Novo, subject to terms) may apply ^[7]. For the telehealth route, the JMIR report recommends dietitian integration or a hybrid model that pairs the prescription with clinical support ^[6].

Sources

1. National Library of Medicine DailyMed. WEGOVY (semaglutide) injection, solution, drug label.
2. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information. Initial U.S. approval: 2022.
3. PMC. Obesity management in primary care: A joint clinical perspective and expert review from the Obesity Medicine Association (OMA) and the American College of Osteopathic Family Physicians (ACOFP). 2025.
4. PMC. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes–2026.
5. Obesity Medicine Association. Find an obesity doctor near you.
6. PMC. After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care.
7. NovoCare Pharmacy. Get your GLP-1 medications delivered with NovoCare Pharmacy.
8. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge.
9. US Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
10. US Food and Drug Administration. FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs.
11. US Food and Drug Administration. FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain.
12. US Food and Drug Administration. BeSafeRx: Your Source for Online Pharmacy Information.
13. Business Group on Health. GLP-1 Costs Loom Large for Employers, Forcing Challenging Coverage Decisions, Business Group on Health Survey Finds.
14. Medicare.gov. Weight loss drugs.
15. Eli Lilly and Company. FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. April 1, 2026.